Pharmacovigilance
-1
archive,category,category-pharmacovigilance,category-4,wp-theme-bridge,wp-child-theme-bridge-child,bridge-core-3.3.5.1,cookies-not-set,qode-optimizer-1.2.3,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-smooth-scroll-enabled,qode-child-theme-ver-1.0.0,qode-theme-ver-30.9.1,qode-theme-bridge,wpb-js-composer js-comp-ver-9.0.1,vc_responsive

#MedSafetyWeek 2026 is here. For Marketing Authorisation Holders, having the mandatory local pharmacovigilance contact in Bulgaria ensures continuous regulatory compliance while making adverse reaction reporting simpler and more accessible. For HCPs, patients, and other reporters, it means direct access to a knowledgeable, approachable specialist who speaks their...

Supplier qualification, ongoing oversight and quality management of subcontractors have always been integral parts of an effective pharmacovigilance (PV) system. In the context of the recent legislative development (Implementing Regulation (EU) 2025/1466) the importance of the contractual clarity with service providers was reinforced and marketing...

The interpretation of day 0 in local literature screening historically encountered challenges, particularly regarding hard copy journals. In January 2023 European Medicines Agency (EMA) posted an interesting view of the Pharmacovigilance Inspectors Working Group regarding Day 0 in the context of Individual Case Safety Reports...

The Announcement of the EMA Management Board earlier in May 2017 confirmed the full functionality of the EudraVigilance database. Hence, the transitional period in pharmacovigilance reporting in the EEA is about to expire. The simplified electronic reporting of suspected adverse reactions related to medicines by...

Following the developments of the pharmacovigilance legislations at EU level Bulgaria imposed the requirement for the appointment by the marketing authorisation holders (MAHs) of a local contact person for pharmacovigilance issues (LPPV) for medicinal products for human use. The national legislation does not contain detailed requirements...